722497-32-7

Usage

Uses

Used in Pharmaceutical Industry:
METHYL 5-BROMO-2-METHOXY-3-METHYLBENZENECARBOXYLATE is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its unique structure and reactivity make it a valuable component in the development of new drugs and therapeutic agents.
Used in Material Science:
METHYL 5-BROMO-2-METHOXY-3-METHYLBENZENECARBOXYLATE is used as a chemical intermediate in the field of material science, where it contributes to the synthesis of novel materials with specific properties. Its versatility in chemical reactions allows for the creation of materials with tailored characteristics for various applications.
Used in Dye Synthesis:
METHYL 5-BROMO-2-METHOXY-3-METHYLBENZENECARBOXYLATE is used as a chemical intermediate in the synthesis of dyes. Its aromatic structure and functional groups enable the production of dyes with specific color properties and stability, which are essential in various industries such as textiles, plastics, and printing.
Used in Polymer Synthesis:
METHYL 5-BROMO-2-METHOXY-3-METHYLBENZENECARBOXYLATE is used as a chemical intermediate in the synthesis of polymers. Its incorporation into polymer structures can lead to the development of new materials with improved properties, such as enhanced strength, flexibility, or thermal stability, which can be utilized in a wide range of applications.

InChI:InChI=1/C10H11BrO3/c1-6-4-7(11)5-8(9(6)13-2)10(12)14-3/h4-5H,1-3H3

Upstream product

• 36194-82-8 5-bromo-2-hydroxy-3-methylbenzenecarboxylic acid 
• 77-78-1 dimethyl sulfate 
• 83-40-9 3-methylsalicylic acid 
• 74-88-4 methyl iodide 

Downstream Products

• 414861-65-7 2-methoxy-5-(5-methoxycarbonyl-pent-1-ynyl)-3-methyl-benzoic acid methyl ester 
• 159121-84-3 5-bromo-2-methoxy-3-methyl-benzoic acid 
• 1427407-43-9 N-(2,6-difluoro-3-hydroxyphenyl)-5-(3-fluorophenyl)-2-methoxy-3-methylbenzamide 
• 1427407-44-0 2,4-difluoro-3-[[5-(3-fluorophenyl)-2-methoxy-3-methylphenyl]methylamino]phenol 
• 1427407-45-1 ethyl 2-[2,4-difluoro-3-[[5-(3-fluorophenyl)-2-methoxy-3-methyl-phenyl]methylamino]phenoxy]acetate 
• 1427406-20-9 C₂₃H₂₀F₃NO₄ 
• 1427407-46-2 C₂₄H₂₂F₃NO₄ 
• 1427406-21-0 C₂₂H₁₈F₃NO₄ 
• 1427407-89-3 N-(6-fluoro-3-hydroxy-2-methylphenyl)-5-(3-fluorophenyl)-2-methoxy-3-methylbenzamide 
• 1427407-90-6 4-fluoro-3-[[5-(3-fluorophenyl)-2-methoxy-3-methylphenyl]methylamino]-2-methylphenol 
• 1427407-91-7 C₂₇H₂₉F₂NO₄ 
• 1427406-33-4 C₂₄H₂₃F₂NO₄ 
• 1427408-08-9 5-(3-fluorophenyl)-N-(3-hydroxy-2,6-dimethylphenyl)-2-methoxy-3-methylbenzamide 
• 1427408-09-0 3-[[5-(3-fluorophenyl)-2-methoxy-3-methylphenyl]methylamino]-2,4-dimethylphenol 

Relevant academic research and scientific papers

ANILINE DERIVATIVES,THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION

The present invention relates to aniline derivatives, to their preparation and to their therapeutic application.

Alkenyldiarylmethanes, Fused Analogs And Syntheses Thereof

Non-nucleoside inhibitors of HIV-1 reverse transcriptase are described. Such inhibitors may be used as part of a combination therapy to treat HIV infection. Compounds described herein exhibit antiviral potency. In addition, compounds described herein exhibit metabolic stability. Also described herein are processes for preparing Non-nucleoside inhibitors of HIV-1 reverse transcriptase.

NK-1 AND SEROTONIN TRANSPORTER INHIBITORS

The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating disorders associated with an excess or imbalance of tachykinins or serotonin or both.

Synthesis, anti-HIV activity, and metabolic stability of new alkenyldiarylmethane HIV-1 non-nucleoside reverse transcriptase inhibitors

Non-nucleoside inhibitors of HIV-1 reverse transcriptase (NNRTIs) are part of the combination therapy currently used to treat HIV infection. Based on analogy with known HIV-1 NNRT inhibitors, 18 novel alkenyldiarylmethanes (ADAMs) containing 5-chloro-2-methoxyphenyl, 3-cyanophenyl, or 3-fluoro-5- trifluoromethylphenyl groups were synthesized and evaluated as HIV inhibitors. Their stabilities in rat plasma have also been investigated. Although introducing 5-chloro-2-methoxyphenyl or 3-fluoro-5-trifluoromethylphenyl groups into alkenyldiarylmethanes does not maintain the antiviral potency, the structural modification of alkenyldiarylmethanes with a 3-cyanophenyl substituent can be made without a large decrease in activity. The oxazolidinonyl group was introduced into the alkenyldiarylmethane framework and found to confer enhanced metabolic stability in rat plasma.

Design, synthesis, anti-HIV activities, and metabolic stabilities of alkenyldiarylmethane (ADAM) non-nucleoside reverse transcriptase inhibitors

The alkenyldiarylmethane (ADAM) HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) are effective anti-HIV agents in cell culture. However, the potential clinical utility of the ADAMs is expected to be limited by the presence of methyl ester mo